本帖最后由 老马 于 2012-1-13 21:20 编辑 l7 v2 Y; ~, ^1 V- n
9 z$ E3 w, B! ?9 b0 R5 N, F爱必妥和阿瓦斯丁的比较% h b* a; s/ W1 I9 s8 w8 h/ @
- K, T: e7 X% [, @3 Z% V# fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 Q7 f% Q; G+ N @
# j+ p$ e9 M, R3 l; D6 w. h& p
. @2 h& h; Z- q# M& I
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' M- d4 @( |( f# Z# h5 k
==================================================
2 K3 l9 A% q5 b4 `+ KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& {' I( z5 U' W) N. x8 UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! f) g \5 X. }9 _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 s9 s' b- f3 I4 C0 P
|